CURR
CURE Pharmaceutical Holding Corp. [CURR] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
CURR Stock Summary
In the News
CURR Financial details
Company Rating
Sell
Market Cap
8.21M
Income
-10.57M
Revenue
4.14M
Book val./share
-0.14
Cash/share
0
Dividend
-
Dividend %
-
Employees
28
Optionable
No
Shortable
Yes
Earnings
02 Sep 2022
P/E
-0.69
Forward P/E
-
PEG
0.13
P/S
1.67
P/B
-1.04
P/C
-
P/FCF
-0.9
Quick Ratio
0.21
Current Ratio
0.24
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.15
EPS next Y
-
EPS next Q
-
EPS this Y
-70.58%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-26.32%
Revenue last 5Y
53%
Revenue Q/Q
4.42%
EPS Q/Q
123.19%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
0.21%
Inst Trans
1%
ROA
-322%
ROE
35%
ROC
0.92%
Gross Margin
67%
Oper. Margin
-148%
Profit Margin
-243%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.03-0.34
52W High
-
52W Low
-
RSI
-
Rel Volume
0.51
Avg Volume
17.66K
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
0.299618
-
-
Volatility
0%, 0%
Prev Close
-
Price
-
Change
-
CURR Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.02 | 0.02 | 0.04 | 0.13 | 0.07 | |
| Net income per share | -0.42 | -0.72 | -0.5 | -0.31 | -0.09 | |
| Operating cash flow per share | -0.16 | -0.23 | -0.21 | -0.09 | -0.14 | |
| Free cash flow per share | -0.17 | -0.25 | -0.22 | -0.09 | -0.14 | |
| Cash per share | 0.02 | 0.12 | 0.04 | 0 | 0.1 | |
| Book value per share | -0.21 | 0.39 | 0.45 | 0.32 | -0.1 | |
| Tangible book value per share | -0.25 | -0.34 | -0.38 | -0.4 | -0.11 | |
| Share holders equity per share | -0.21 | 0.39 | 0.45 | 0.32 | -0.1 | |
| Interest debt per share | 0.37 | 0.14 | 0.4 | 0.29 | 0.15 | |
| Market cap | 37.5M | 103.62M | 61.5M | 18.07M | 11.02M | |
| Enterprise value | 43.27M | 100.32M | 76.1M | 31.96M | 14.13M | |
| P/E ratio | -3.61 | -4.16 | -2.59 | -1.14 | -1.72 | |
| Price to sales ratio | 64.22 | 166.33 | 29.99 | 2.76 | 2.25 | |
| POCF ratio | -9.15 | -12.79 | -6.33 | -4.19 | -1.09 | |
| PFCF ratio | -8.85 | -12.11 | -5.91 | -4.08 | -1.09 | |
| P/B Ratio | -7.25 | 7.67 | 2.89 | 1.12 | -1.55 | |
| PTB ratio | -7.25 | 7.67 | 2.89 | 1.12 | -1.55 | |
| EV to sales | 74.09 | 161.02 | 37.11 | 4.88 | 2.89 | |
| Enterprise value over EBITDA | -6.17 | -8.38 | -3.54 | -2.86 | -2.12 | |
| EV to operating cash flow | -10.55 | -12.38 | -7.83 | -7.41 | -1.4 | |
| EV to free cash flow | -10.21 | -11.72 | -7.31 | -7.21 | -1.4 | |
| Earnings yield | -0.28 | -0.24 | -0.39 | -0.87 | -0.58 | |
| Free cash flow yield | -0.11 | -0.08 | -0.17 | -0.25 | -0.91 | |
| Debt to equity | -1.21 | 0.06 | 0.77 | 0.86 | -1.42 | |
| Debt to assets | 1.85 | 0.02 | 0.35 | 0.34 | 1.47 | |
| Net debt to EBITDA | -0.82 | 0.28 | -0.68 | -1.25 | -0.47 | |
| Current ratio | 0.19 | 0.52 | 0.27 | 0.07 | 0.68 | |
| Interest coverage | -2.49 | -2.93 | -5.33 | -30.45 | -39.29 | |
| Income quality | 0.39 | 0.38 | 0.32 | 0.33 | 0.39 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 11.05 | 16.24 | 5.54 | 2.88 | 1.62 | |
| Research and developement to revenue | 2.41 | 3.7 | 1.36 | 0.36 | 0.01 | |
| Intangibles to total assets | 0.36 | 0.78 | 0.85 | 0.89 | 0.05 | |
| Capex to operating cash flow | 0.03 | 0.06 | 0.07 | 0.03 | 0 | |
| Capex to revenue | -0.24 | -0.74 | -0.34 | -0.02 | 0 | |
| Capex to depreciation | -0.92 | -0.79 | -0.73 | -0.03 | 0 | |
| Stock based compensation to revenue | 4.21 | 6.64 | 1.67 | 0.59 | 0.33 | |
| Graham number | 1.39 | 2.52 | 2.26 | 1.51 | 0.46 | |
| ROIC | -6.88 | -0.98 | -0.27 | -0.67 | -5.88 | |
| Return on tangible assets | -4.75 | -3.46 | -3.45 | -3.57 | -0.98 | |
| Graham Net | -0.32 | -0.42 | -0.49 | -0.47 | -0.07 | |
| Working capital | -6.96M | -5.65M | -10.62M | -22.48M | -4.39M | |
| Tangible asset value | -6.36M | -11.77M | -18.19M | -20.04M | -7.37M | |
| Net current asset value | -6.96M | -12.77M | -21.23M | -22.68M | -4.39M | |
| Invested capital | -1.21 | 0.06 | 0.77 | 0.86 | -1.42 | |
| Average receivables | 56.51K | 122.4K | 183K | 290.5K | 1.38M | |
| Average payables | 659.68K | 1.02M | 1.7M | 3.35M | 3.61M | |
| Average inventory | 41.39K | 96.89K | 302.5K | 656.5K | 504.5K | |
| Days sales outstanding | 64.26 | 83.19 | 39.86 | 19.88 | 178.85 | |
| Days payables outstanding | 1.01K | 1.99K | 724.23 | 767.63 | 621.23 | |
| Days of inventory on hand | 49.26 | 246.49 | 152.31 | 145.13 | 33.99 | |
| Receivables turnover | 5.68 | 4.39 | 9.16 | 18.36 | 2.04 | |
| Payables turnover | 0.36 | 0.18 | 0.5 | 0.48 | 0.59 | |
| Inventory turnover | 7.41 | 1.48 | 2.4 | 2.52 | 10.74 | |
| ROE | 2.01 | -1.84 | -1.12 | -0.98 | 0.9 | |
| Capex per share | -0.01 | -0.01 | -0.01 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.03 | 0.01 | 0.02 | 0.01 | 0.01 | |
| Net income per share | -0.05 | -0.1 | 0 | -0.01 | -0.03 | |
| Operating cash flow per share | -0.07 | -0.02 | -0.02 | -0.02 | 0 | |
| Free cash flow per share | -0.07 | -0.02 | -0.02 | -0.02 | 0 | |
| Cash per share | 0.06 | 0.04 | 0.02 | 0 | 0 | |
| Book value per share | 0 | -0.1 | -0.1 | -0.11 | -0.14 | |
| Tangible book value per share | -0.09 | -0.1 | -0.1 | -0.11 | -0.14 | |
| Share holders equity per share | 0 | -0.1 | -0.1 | -0.11 | -0.14 | |
| Interest debt per share | 0.15 | 0.14 | 0.14 | 0.11 | 0 | |
| Market cap | 18.27M | 11.21M | 11.86M | 7.68M | 7.95M | |
| Enterprise value | 24.6M | 18.32M | 18.91M | 15.41M | 7.76M | |
| P/E ratio | -1.27 | -0.39 | -14.18 | -1.95 | -0.89 | |
| Price to sales ratio | 10.24 | 12.27 | 9.58 | 7.91 | 7.83 | |
| POCF ratio | -3.72 | -7.07 | -8.44 | -6.44 | 0 | |
| PFCF ratio | -3.72 | -7.07 | -8.23 | -6.39 | 0 | |
| P/B Ratio | -105.62 | -1.58 | -1.67 | -0.98 | -0.8 | |
| PTB ratio | -105.62 | -1.58 | -1.67 | -0.98 | -0.8 | |
| EV to sales | 13.79 | 20.07 | 15.28 | 15.85 | 7.64 | |
| Enterprise value over EBITDA | -10.54 | -9.63 | -11.93 | -8.62 | -3.49 | |
| EV to operating cash flow | -5 | -11.55 | -13.46 | -12.91 | 0 | |
| EV to free cash flow | -5 | -11.55 | -13.14 | -12.82 | 0 | |
| Earnings yield | -0.2 | -0.64 | -0.02 | -0.13 | -0.28 | |
| Free cash flow yield | -0.27 | -0.14 | -0.12 | -0.16 | 0 | |
| Debt to equity | -62.26 | -1.42 | -1.4 | -1 | 0 | |
| Debt to assets | 0.72 | 1.47 | 1.91 | 2.13 | 0 | |
| Net debt to EBITDA | -2.71 | -3.74 | -4.45 | -4.32 | 0.08 | |
| Current ratio | 0.55 | 0.43 | 0.35 | 0.24 | 0.15 | |
| Interest coverage | -364 | -26.43 | -120.29 | -115.08 | 148.27 | |
| Income quality | 1.37 | 0.22 | 6.72 | 1.21 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 2.02 | -1.69 | 1.48 | 1.9 | 0 | |
| Research and developement to revenue | 0 | 0.23 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.42 | 0.05 | 0.07 | 0.09 | 0.11 | |
| Capex to operating cash flow | 0 | 0 | 0.02 | 0.01 | 0 | |
| Capex to revenue | 0 | 0 | -0.03 | -0.01 | 0 | |
| Capex to depreciation | 0 | 0 | -0.92 | -0.2 | 0 | |
| Stock based compensation to revenue | 0.3 | 0.23 | 0.17 | 0.23 | 0 | |
| Graham number | 0.05 | 0.47 | 0.08 | 0.18 | 0.31 | |
| ROIC | -0.25 | -0.61 | -0.56 | -10.98 | 0.22 | |
| Return on tangible assets | -0.41 | -1.09 | -0.04 | -0.29 | -0.89 | |
| Graham Net | -0.12 | -0.13 | -0.13 | -0.13 | -0.16 | |
| Working capital | -6.81M | -7.99M | -8.02M | -8.76M | -10.81M | |
| Tangible asset value | -6.41M | -7.42M | -7.44M | -8.2M | -10.29M | |
| Net current asset value | -6.89M | -8.03M | -8.03M | -8.76M | -10.81M | |
| Invested capital | -62.26 | -1.42 | -1.4 | -1 | 0 | |
| Average receivables | 1.6M | 2.53M | 2.36M | 2.27M | 1.81M | |
| Average payables | 2.4M | 1.35M | 1.06M | 1.17M | 1.42M | |
| Average inventory | 644.5K | 392.5K | 223K | 291K | 250.5K | |
| Days sales outstanding | 134.19 | 236.48 | 168.73 | 205.56 | 123.69 | |
| Days payables outstanding | 415.62 | 134.24 | 366.9 | 410.83 | 508.6 | |
| Days of inventory on hand | 161.8 | 18.28 | 103.79 | 90.97 | 71.22 | |
| Receivables turnover | 0.67 | 0.38 | 0.53 | 0.44 | 0.73 | |
| Payables turnover | 0.22 | 0.67 | 0.25 | 0.22 | 0.18 | |
| Inventory turnover | 0.56 | 4.92 | 0.87 | 0.99 | 1.26 | |
| ROE | 20.77 | 1.01 | 0.03 | 0.13 | 0.22 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
CURR Frequently Asked Questions
What is CURE Pharmaceutical Holding Corp. stock symbol ?
CURE Pharmaceutical Holding Corp. is a US stock , located in Oxnard of Ca and trading under the symbol CURR
What is CURE Pharmaceutical Holding Corp. stock quote today ?
CURE Pharmaceutical Holding Corp. stock price is $- today.
Is CURE Pharmaceutical Holding Corp. stock public?
Yes, CURE Pharmaceutical Holding Corp. is a publicly traded company.
Company Profile
- Volume Average 17.66K
- Market Capitalization 8.21M
- Employee 28
- CEO Ms. Nancy Duitch
- Headquarters Oxnard,CA,US
- IPO Date 2017-02-03
-
Website
https://www.curepharmaceutical.com 
CURE Pharmaceutical Holding Corp., a biopharmaceutical company, focuses on the development and manufacturing of drug formulation and drug delivery technologies to enhance drug safety, efficacy, and patient adherence. It operates through two segments, Cure and Sera Labs. The company's pharmaceutical drug programs include CUREfilm Blue, a sildenafil oral thin film (OTF) for the treatment of erectile dysfunction; CUREfilm Canna, a cannabinoid product with optimized pharmacokinetic profiles using microCURE and CUREfilm technology; CUREfilm Anti-Viral, an orally bio-available anti-viral of an existing therapeutic leveraging existing pre-clinical/clinical safety and toxicity data; and CUREfilm Central Nervous System, a novel dosage form to treat mental health disorders, such as depression, PTSD, addiction disorders, obsessive compulsive disorders, and anxiety. It also sells various wellness products under its distribution partners' brands. In addition, the company develops 50,000IU and Vitamin D3 OTF for oral administration. It has a licensing agreement with Canopy Growth Corporation. The company was founded in 2011 and is headquartered in Oxnard, California.
